Teva Pharmaceutical Industries (TEVA) announced that it has successfully priced its debt offering for $15B worth of senior notes, maturing between 2018 and 2046, to help fund its acquisition of Allergan's (AGN) generic business. CFO Eyal Desheh said that the strength f the demand, which was multiple times the size of the offering, and the attractive prices, are a testament to Teva's financial strength and strong reputation with investors.